Novel prognostic tissue markers in congestive heart failure

Stone, James R.

doi:10.1016/j.carpath.2014.07.010

Cited by 7 publications

(3 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9) Appropriate prognostic risk stratification may help clinicians better manage patients by assessing mortality risk. Recent studies have been attempting to identify novel biomarkers such as ubiquitin, Gremlin-1, cyclophilin A, pentraxin-3, and heterogeneous nuclear ribonucleoprotein C. [10][11][12] In our study, we enrolled 287 subjects in order to explore the easily measured and complementary long-term prognostic factors ST2, NT-proBNP, and serum sodium in AHF patients receiving standard treatment according to the guideline. Our goals were to clarify the roles of these 3 variables as indicators of AHF prognosis and to investigate the specific cut-off level for risk stratification.…”

mentioning

confidence: 99%

Predictors of Long-Term Mortality in Patients With Acute Heart Failure

et al. 2017

View full text Add to dashboard Cite

SummaryTo investigate parameters which were related with long-term mortality in patients hospitalized for acute heart failure (AHF).A total of 287 patients with AHF presenting to the First Affiliated Hospital of Nanjing Medical University were enrolled into the registry from April 2012 to January 2015. The primary endpoint was all-cause mortality within 1 year; the association between variables and prognosis was assessed after 1 year.Among the 287 patients, 17 did not continue follow-up and 47 (17.4%) passed away. Baseline NT-proBNP and sST2 concentrations were higher amongst deceased than among survivors (P < 0.001). Serum sodium concentrations of patients who died were lower (P < 0.001). In receiver operator characteristics (ROC) analyses, the area under the curve (AUC) values for NT-proBNP, sST2, and serum sodium to predict 1-year mortality were 0.699 (95%CI 0.639-0.755), 0.692, (95%CI 0.634-0.747), and 0.694 (95%CI 0.634-0.750), respectively. The optimal cut-off points for NT-proBNP, sST2, and serum sodium were 2137.0 ng/L, 35.711 ng/mL, and 136.6 mmol/L, respectively. In Cox regression analysis, ln-transformed NT-proBNP (HR 1.546, P = 0.039), ln-transformed sST2 (HR1.542, P = 0.049), and serum sodium (HR 0.880, P = 0.000) values reliably predicted long-term mortality after multivariable adjustment.In patients with acute heart failure, NT-proBNP, sST2 and serum sodium are potential predictors of 1-year mortality. (Int Heart J 2017; 58: 409-415)

show abstract

mentioning

confidence: 99%

Predictors of Long-Term Mortality in Patients With Acute Heart Failure

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A N U S C R I P T 7 criteria (and serum analytes) for stratifying risk in heart failure patients [48]. With the increasing application of immune checkpoint inhibitors (ICI) in cancer therapeutics, the EMB has also assumed new importance in the early diagnosis of potentially fatal immune checkpoint inhibitor (ICI) myocarditis [49].…”

Section: A C C E P T E D Mmentioning

confidence: 99%

Pathobiology of cardiovascular diseases: an update

Buja

Ottaviani

Mitchell

2019

Cardiovascular Pathology

View full text Add to dashboard Cite

This article introduces the Second Special Issue of Cardiovascular Pathology (CVP), the official journal of the Society for Cardiovascular Pathology (SCVP). This CVP Special Issue showcases a series of commemorative review articles in celebration of the 25 th anniversary of CVP originally published in 2016, and now compiled into a virtual collection with online access for the cardiovascular pathology community. This overview also provides updates on the major categories of cardiovascular diseases from the perspective of cardiovascular pathologists, highlighting publications from CVP, as well as additional important review articles and clinicopathologic references.

show abstract

“…3,4) Endomyocardial biopsy (EMB) has been used to diagnose specific diseases in patients with nonischemic HF, such as dilated and hypertophic cardiomyopathy, amyloidosis, myocarditis, Fabry disease, and sarcoidosis. 5,6) Morphologic abnormalities (e.g., cardiomyocyte size), area of the cardiomyocyte nucleus, myofibril volume fraction, interstitial volume density, extent of extracellular matrix (ECM), and fibrosis area in the myocardium are factors that need to be observed. Moreover, there may be molecular alterations in EMB specimens that might serve as sensitive and specific markers of the outcome in HF patients.…”

mentioning

confidence: 99%

Analysis of the Correlation between the Myocardial Expression of DPP-4 and the Clinical Parameters of Patients with Heart Failure

et al. 2018

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as antidiabetic drugs. We recently reported that DPP-4 inhibition has beneficial effects on heart failure (HF) mice model. Furthermore, we confirmed that myocardial DPP-4 activity was significantly increased in HF mice compared with non-HF mice. The aim of this study was to investigate the level of myocardial CD26 (DPP-4) expression and its association to clinical parameters in HF patients.Endomyocardial biopsy (EMB) specimens (n = 33) were obtained from HF patients who were admitted to Chiba University Hospital from June 2006 to July 2012. EMB specimens were fixed in formaldehyde and stained with Masson's trichrome staining or with anti-CD26 antibody. Patients were divided into the high CD26 density (CD26-H) or low CD26 density groups (CD26-L). DPP-4 density was compared with blood brain natriuretic peptide (BNP) level and echocardiographic parameters at one year after EMB. Although there were no significant differences in echocardiographic parameters between the CD26-H group and CD26-L group, blood BNP levels were higher in the CD26-H group than in the CD26-L group at one year after EMB. Multivariate regression analysis showed that CD26 density was also an independent determinant of blood BNP levels at one year after EMB.The level of myocardial CD26 expression might be a predictive marker of prognosis in patients with HF. (Int Heart J 2018; 59: 1303-1311

show abstract

Novel prognostic tissue markers in congestive heart failure

Cited by 7 publications

References 54 publications

Predictors of Long-Term Mortality in Patients With Acute Heart Failure

Predictors of Long-Term Mortality in Patients With Acute Heart Failure

Pathobiology of cardiovascular diseases: an update

Analysis of the Correlation between the Myocardial Expression of DPP-4 and the Clinical Parameters of Patients with Heart Failure

Contact Info

Product

Resources

About